HCV epidemiology in high-risk groups and the risk of reinfection Håvard Midgard, Amanda Weir, Norah Palmateer, Vincent Lo Re, Juan A. Pineda, Juan Macías, Olav Dalgard  Journal of Hepatology  Volume 65, Issue 1, Pages S33-S45 (October 2016) DOI: 10.1016/j.jhep.2016.07.012 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Prevalence of antibodies to hepatitis C virus (anti-HCV) in the WHO European region, by country. (A) Across the general population. (B) Across the population of people who inject drugs (PWID). Dotted areas indicate countries outside the WHO European region. Adapted from Hope et al. 2014 [17]. Journal of Hepatology 2016 65, S33-S45DOI: (10.1016/j.jhep.2016.07.012) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Recurrence of HCV RNA after sustained virological response. This could result from either (A) late relapse of a majority variant, (B) persistence/re-emergence of a pre-existing minority variant, or (C) reinfection with a new viral strain. TW0, treatment week 0; EOT, end of treatment; SVR, sustained virological response; LOD, level of detection. Journal of Hepatology 2016 65, S33-S45DOI: (10.1016/j.jhep.2016.07.012) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions